Pharmacokinetics of acemetacin and its active metabolite indomethacin in rats during acute hepatic damage and liver regeneration
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 2
Abstract
Background and aim: The pharmacokinetics of acemetacin, a non-steroidal anti-inflammatory drug which is biotransformed to indomethacin by hepatic first-pass effect, was examined during the necrotic and regeneration phases resulting from acute hepatitis induced by carbon tetrachloride (CCl4). Material and methods: Acute hepatitis was induced by oral CCl4 administration to male Wistar rats. On days 0, 1 and 3 after the insult, liver histological analysis was performed, biochemical markers of liver damage and regeneration were measured, and the pharmacokinetics of oral acemetacin and of its active metabolite, indomethacin, were determined. Results: One day after CCl4 administration, liver necrosis was apparent and there was an increase in the circulating levels of indicators of liver damage and regeneration with regard to control conditions. Acemetacin bioavailability was increased, although not in a statistically significant manner. On the other hand, indomethacin bioavailability was significantly reduced. By day 3, histological analysis revealed liver recovery, although not complete, while biochemical indicators of hepatic damage had reverted either totally or partially. Markers of liver regeneration were still increased. Bioavailability acemetacin and indomethacin was comparable to control values. In conclusion: Indomethacin bioavailability after oral administration of its precursor, acemetacin, is significantly reduced by acute hepatitis produced by CCl4. Pharmacokinetic alterations, as liver damage, are reversible, but do not require complete liver regeneration to return to basal conditions.
Authors and Affiliations
Aracely Chávez-Piña, Liliana Favari, Gilberto Castañeda-Hernández
Keywords
Related Articles
- EP ID EP77857
- DOI -
- Views 115
- Downloads 0
Latin American Association for the Study of the Liver Practice Guidelines Diagnosis, management, and treatment of hepatitis C This document has been approved by the Latin American Association for the Study of the Liver (ALEH)
Association of a novel TAS2R38 haplotype with alcohol intake among Mexican-Mestizo population
Background. Alcohol intake has been associated with the bitter taste receptor T2R38. TAS2R38 gene expresses two common haplotypes: PAV and AVI. It has been reported that AVI homozygotes consume more alcohol than heterozy...
Bile salt export pump deficiency disease: two novel, late onset, ABCB11 mutations identified by next generation sequencing
Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of autosomal recessive cholestatic diseases of childhood and represents the main indication for liver transplantation at this age; PFIC2 invo...
Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature
Flutamide is a non-steroidal anti-androgenic drug, commonly used in the treatment of advanced prostate cancer, acne and hirsutism. This drug may induce various degrees of liver injury, including acute liver failure (ALF)...
Cultural validation of the post-Liver transplant quality of life (pLTQ) questionnaire for the Brazilian population
Background and rationale. The post-Liver Transplant Quality of Life (pLTQ) questionnaire, developed in the United States, is adisease-targeted instrument designed to evaluate health-related quality of life (HRQoL) in li...